Angiotensin 1/2 (5-7): A Potent Vasoconstrictor Peptide for Renin-Angiotensin System Research

Executive Summary: Angiotensin 1/2 (5-7) (H2N-Ile-His-Pro-OH) is a short oligopeptide derived from angiotensinogen and acts as a potent vasoconstrictor, directly impacting blood pressure regulation (Oliveira et al., 2025). Its molecular weight is 365.43 Da and molecular formula is C17H27N5O4, with high solubility in DMSO, ethanol, and water at room temperature (see product page). The peptide plays a critical role in the renin-angiotensin system (RAS), modulating vascular tone and fluid balance. Recent evidence demonstrates its involvement in enhancing SARS-CoV-2 spike protein binding to cellular receptors, with implications for viral pathogenesis research (DOI). APExBIO’s A1049 kit is validated at ≥98.36% purity by HPLC and confirmed with mass spectrometry, ensuring reproducibility for experimental workflows.

Biological Rationale

Angiotensin 1/2 (5-7) is a minimal, biologically active peptide sequence (Ile-His-Pro) derived from the N-terminal region of angiotensinogen, a serum globulin synthesized in the liver (Oliveira et al., 2025). The renin-angiotensin system (RAS) is a central regulator of blood pressure, electrolyte balance, and systemic vascular resistance. Angiotensin peptides are generated through sequential enzymatic cleavage: renin converts angiotensinogen to angiotensin I (1–10), which is further processed by angiotensin-converting enzyme (ACE) and other peptidases to produce shorter, bioactive fragments such as angiotensin II (1–8), angiotensin (1–7), and angiotensin 1/2 (5-7) (DOI). These peptides exert distinct, receptor-mediated effects on vascular smooth muscle cells, kidney function, and fluid homeostasis.

Mechanism of Action of Angiotensin 1/2 (5-7)

Angiotensin 1/2 (5-7) acts as a potent vasoconstrictor, primarily by activating G protein-coupled receptors (GPCRs) on vascular smooth muscle cells. The peptide’s sequence (Ile-His-Pro) is sufficient to induce a contractile response in isolated vessel models (DOI). Unlike its precursor angiotensin I, which is biologically inactive, Angiotensin 1/2 (5-7) causes rapid increases in blood pressure through direct vasoconstriction. It also displays dipsogenic activity, stimulating thirst and fluid intake, which further influences systemic fluid balance. In the context of viral pathogenesis, shorter angiotensin fragments, including 1/2 (5-7), have been shown to enhance the binding of the SARS-CoV-2 spike protein to host cell receptors, particularly AXL, beyond the effects observed with longer angiotensin peptides (DOI).

Evidence & Benchmarks

• Angiotensin 1/2 (5-7) (Ile-His-Pro) increases vascular tone in ex vivo aortic ring assays, demonstrating vasoconstrictor potency comparable to longer angiotensin fragments (Oliveira et al., 2025).
• Short N-terminal deletion fragments (e.g., angiotensin 1/2 (5-7)) enhance SARS-CoV-2 spike protein binding to the AXL receptor by more than two-fold, supporting their role in viral entry facilitation (DOI).
• Purity of APExBIO A1049 is validated at 98.36% by HPLC and confirmed by mass spectrometry under standard storage at -20°C (APExBIO product page).
• Solubility benchmarks: ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, and ≥50 mg/mL in water, at ambient temperature; solutions should be used immediately for stability (APExBIO).
• Comparative studies show that C-terminal deletions of angiotensin II reduce, while N-terminal deletions (1/2 (5-7) included) increase, the ability to enhance viral spike–AXL binding (Oliveira et al., 2025).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is a valuable tool for dissecting mechanisms of blood pressure regulation, hypertension, and peptide-receptor interactions in both animal models and cell-based assays. Its recently characterized role in potentiating SARS-CoV-2 spike protein–AXL binding extends its relevance to virology and infectious disease research. The peptide’s robust solubility profile allows integration into a wide range of experimental systems, including high-throughput screening, functional vasoreactivity assays, and viral entry models. For advanced workflows, see strategic discussion in this mechanistic overview (this article extends mechanistic context with new viral insights). For optimization tips and troubleshooting, this workflow guide summarizes comparative solubility and bioactivity; our article adds recent virology benchmarks. For a deep dive into vasoconstrictor mechanisms, see this focused analysis, while our review updates the scope with new SARS-CoV-2 findings.

Common Pitfalls or Misconceptions

• Not a direct ACE inhibitor: Angiotensin 1/2 (5-7) does not inhibit angiotensin-converting enzyme activity; it is a downstream RAS effector peptide.
• Not effective for chronic hypertension models alone: Due to rapid metabolism, its vasoconstrictor effect is acute and transient.
• Not a selective ligand for AT1R or AT2R: The short tripeptide may activate alternative GPCRs or non-canonical pathways.
• Does not substitute for full-length angiotensin II in all signaling studies: Some receptor-mediated responses require the full octapeptide.
• Stability limitation: A1049 solutions must be used promptly; long-term storage of reconstituted peptide leads to degradation and loss of activity.

Workflow Integration & Parameters

For experimental use, APExBIO’s Angiotensin 1/2 (5-7) (A1049) is supplied as a solid and should be stored at -20°C. For solution preparation, dissolve at concentrations ≥36.5 mg/mL in DMSO, or ≥50 mg/mL in ethanol or water. Solutions are most stable when freshly prepared; avoid repeated freeze-thaw cycles. Quality control includes HPLC purity (98.36%) and mass spectrometry confirmation. Shipping is on blue ice, ensuring compound integrity. For detailed protocol integration and troubleshooting, consult this comparative workflow guide.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a validated, high-purity peptide hormone that enables advanced research in cardiovascular physiology, hypertension, and viral pathogenesis. Its unique mechanistic features—potent vasoconstriction, acute physiological effects, and facilitation of viral spike–receptor interactions—make it a critical tool for RAS and emerging infectious disease studies. APExBIO’s stringent QC and robust solubility parameters ensure reproducibility and translational impact. Looking forward, further structural and functional studies on angiotensin peptide variants may reveal new therapeutic and diagnostic opportunities in both cardiovascular and virology domains.